Figure 5.

VHH‐72 competes with ACE2 and multiple classes of SARS‐CoV‐2 antibodies for binding to the receptor‐binding domain. The epitope of VHH‐72 was analyzed via competition analysis using SARS‐CoV‐2 RBD. First, ACE2 receptor and distinct classes of antibodies (0.05–500 nm) were incubated with biotinylated RBD (5 nm). Next, the mixtures were incubated with yeast displaying monovalent VHH‐72, and the relative % RBD binding to VHH‐72 was evaluated via flow cytometry. The data are averages of two independent repeats, and the error bars are standard deviations.